Differential expression of the MYC‐Notch axis drives divergent responses to the front‐line therapy in central and peripheral extensive‐stage small‐cell lung cancer

Documenti analoghi

• Induction immunochemotherapy followed by definitive chemoradiotherapy for unresectable locally advanced non‐small cell lung cancer: a multi‐institutional retrospective cohort study
  di: Leilei Wu, et al.
  Pubblicazione: (2024)
• Camrelizumab, an Anti‐PD‐1 Monoclonal Antibody, Plus Carboplatin and Nab‐Paclitaxel as First‐Line Setting for Extensive‐Stage Small‐Cell Lung Cancer: A Phase 2 Trial and Biomarker Analysis
  di: Jia Yu, et al.
  Pubblicazione: (2025)
• Nanobody‐Mediated c‐MYC Degradation Inhibits Tumor Cell Progression
  di: Yuanyuan Xue, et al.
  Pubblicazione: (2026)
• Targeting polymorphonuclear myeloid‐derived suppressor cells in the immunosuppressive tumor microenvironment for cancer immunotherapy
  di: Shiqi Li, et al.
  Pubblicazione: (2024)
• Nitrate Enhances Gastric Mucosa Defense and Repair Process in Ethanol‐Induced Gastric Ulcer Rats via the Notch–Tff2 Pathway
  di: Ying Liu, et al.
  Pubblicazione: (2026)